Cargando…
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
Wet age-related macular degeneration (AMD) is the most common reason for vision loss in the United States. Many treatments, such as laser therapy and photodynamic therapies, have been used but their efficacy is limited. Emerging anti-vascular endothelial growth factor (VEGF) therapies are now consid...
Autores principales: | Thomas, Michael, Mousa, Shaymaa S, Mousa, Shaker A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595183/ https://www.ncbi.nlm.nih.gov/pubmed/23503202 http://dx.doi.org/10.2147/OPTH.S29974 |
Ejemplares similares
-
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg, Justus G
Publicado: (2019) -
Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015) -
The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022) -
Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013) -
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
por: Garba, Adinoyi O., et al.
Publicado: (2010)